Klinikum der Universität München-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2021

  1. Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015)

    Frontiers in Pharmacology, Vol. 12

  2. Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation

    British Journal of Clinical Pharmacology, Vol. 87, Núm. 3, pp. 988-1000

  3. Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies

    Pharmacoepidemiology and Drug Safety, Vol. 30, Núm. 10, pp. 1339-1352

  4. Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban—A European comparative drug utilization study

    Basic and Clinical Pharmacology and Toxicology, Vol. 128, Núm. 3, pp. 440-454

2019

  1. Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A cross-national drug utilization study

    British Journal of Clinical Pharmacology, Vol. 85, Núm. 11, pp. 2524-2539

2017

  1. A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events

    Journal of Clinical Epidemiology, Vol. 86, pp. 168-175